Form 4: Werewolf Therapeutics Director Sells Shares

Werewolf Therapeutics Director Luke Evnin sold 177,145 shares of common stock over three days in late October 2025, pursuant to a pre-arranged 10b5-1 plan.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), reported the sale of 177,145 shares of common stock over three separate transactions.
• The transactions were executed pursuant to a Rule 10b5-1 plan established on September 24, 2025.
• On October 27, 2025, 46,664 shares were sold at a weighted average price of $1.72 per share, leaving 4,263,196 shares beneficially owned indirectly.
• On October 28, 2025, 44,327 shares were sold at a weighted average price of $1.64 per share, reducing indirect beneficial ownership to 4,218,869 shares.
• On October 29, 2025, 86,154 shares were sold at a weighted average price of $1.55 per share, resulting in 4,132,715 shares indirectly beneficially owned.
• The shares were sold through various MPM entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P.
• Luke Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant insider selling by a director. While the sales were pre-scheduled under a 10b5-1 plan, which mitigates some of the negative implications, the sheer volume and the declining average sale price over the transaction period still suggest a cautious outlook from a key insider.

Negatives

• A director selling a significant number of shares, even under a 10b5-1 plan, can be perceived as a negative signal regarding the company's near-term prospects or valuation.
• The weighted average sale price decreased over the three days of transactions, from $1.72 to $1.55, which could indicate a declining market price during the selling period.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide specific industry context beyond the company's identity as a biotechnology firm. Insider selling activity is a common occurrence across all industries, and its interpretation often depends on broader market conditions and company-specific news.

Stakeholder Impact

• Shareholders may perceive the director's selling activity as a negative signal, potentially leading to increased scrutiny of the company's performance and future outlook.
• The market price of Werewolf Therapeutics' stock could experience downward pressure following the disclosure of these insider sales.

Key Dates

Recommendation

While the director's sales were pre-scheduled under a 10b5-1 plan, the significant volume and declining average sale price could signal a lack of strong conviction in the company's short-term growth or valuation. Investors should monitor future insider activity and company performance closely, but without additional negative catalysts, a 'hold' recommendation is appropriate rather than an outright 'sell'.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Selling, Form 4, Stock Sale, 10b5-1 Plan, Director Transaction, Biotechnology